TickerTalks
Browse all tickers →
TickerTalks›$ATAI
ATATAI

Atai Beckley Inc.

$ATAI·$1.9B·Biotechnology·Healthcare
$7.15+33.4%YTD+70.6%1Y+102.3%
Mentions · last 7 days
2026-07-10: 20 posts2026-07-11: 9 posts2026-07-12: 20 posts2026-07-13: 44 posts2026-07-14: 82 posts2026-07-15: 199 posts2026-07-16: 899 posts1,276+60%
Price updated 13h ago·X counts updated 13h ago
ATATAI
$ATAIAtai Beckley Inc.
$7.15+33.40%1.3k posts+60%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ATAI, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-17

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Eli Lilly just agreed to buy this psychedelic biotech at $6.75 cash plus CVRs — deal-arb has taken over.

ATAI Life Sciences (now AtaiBeckley after the merger with Beckley Psytech) is a clinical-stage psychedelic-medicine company focused on treatment-resistant depression and adjacent CNS conditions. This week's news changes everything about how the equity trades.

What matters right now:

  • A definitive merger is on the tape: Eli Lilly agreed on July 15 to acquire ATAI for $6.75/share cash plus one CVR — the equity that was a science story is now a deal-arb setup with a defined near-term outcome.
  • The tape has already responded: shares up 33% today to $7.15, above the $6.75 cash — the market is pricing in incremental CVR value that has to be justified by whatever milestone or contingent payment the CVR mechanic covers.
  • The standalone business justified none of this: Q1 revenue of $1M, operating margin negative 3,240%, and analyst FY27 EPS estimate of negative $0.43 — this was a burn-driven clinical company, and Lilly is buying the pipeline (BPL-003 5-MeO-DMT for TRD is the reference asset) plus the platform.
  • Compass Pathways' six-month psilocybin data reinforced the sector re-rating in parallel — Lilly is buying at a moment when the whole psychedelic-medicine category is being taken seriously by big pharma.
  • Class-action law-firm 'M&A investigation' press releases have started — routine boilerplate for any announced deal, not a substantive challenge.

The forward view: the trade over the next 60-90 days is about (a) whether a topping bid emerges from J&J or another big pharma (unlikely but not zero given the sector re-rating), and (b) how the market values the CVR. What crystalizes the trade: Lilly's proxy filing detailing CVR terms and milestone triggers. What breaks it lower: a shareholder vote fight or an antitrust hold-up. This is now an arbitrage position, not an investment in psychedelic medicine.

Agrees with X sentimentThe bullish X read on the buyout speculation was directionally right in advance of the announcement, and the sector-momentum framing (Compass data + J&J Ads) matches the environment. Our take: the science thesis is now secondary to the deal mechanics.

What to watch: Lilly's proxy filing detailing the CVR terms and any interloper bid from J&J or another big pharma; a shareholder-vote fight or antitrust hold-up is what would break the deal-arb narrative.

On the calendar: Merger closing timeline post-Lilly proxy filing

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment19 posts analyzed · as of 2026-07-15

atai Life Sciences chatter is bullish psychedelic-sector momentum. ATAI is up 4 straight days and breaking out of a 4-year base above the ATH AVWAP. Community amplifies buyout-rumor speculation and notes 'if $ATAI gets bought I can finally put my phone down.' A potential $ATAI deal could involve the whole company (not just BPL-003), and J&J is running Google Ads for competing products. Wave-3 chart bulls target $65 with $18 as ideal entry. Community praises DFTX and ATAI outperformance versus XBI and broader market. Compass Pathways' six-month psilocybin data reinforces the sector rally. No bear thread.

Read the AI verdict + X sentiment for $ATAI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech using psychedelic-derived compounds including psilocybin analogues to treat depression and addiction disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ATAI.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $ATAI

Partial — Clinical-stage biotech using psychedelic-derived compounds including psilocybin analogues to treat depression and addiction disorders; the GLP-1 pipeline bifurcation and ADA oral formulation competition is a secondary rather than primary near-term earnings catalyst.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-53.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-36.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-8.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
416.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-366%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
82.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 12, 2026$-0.08$-0.11+27.3%
Q4 2025Mar 6, 2026$-0.05$-0.12+58.3%
Q3 2025Nov 12, 2025$-0.28$-0.12-133.3%
Q2 2025Aug 14, 2025$-0.14$-0.12-16.7%
Next earningsThu, Aug 13·consensus EPS $-0.10

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$954K-38.6%82.5%-3239%$-0.13$-21.1M
Q4 FY25$1.1M-21420.0%100%-4032%$-2.45$-48.3M
Q3 FY25$749K+1772.5%68.9%-3797%$-0.28$-28.6M
Q2 FY25$719K+163.4%68.4%-3515%$-0.14$-19.2M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.5M$944K – $2.5M-$0.43-$0.70 – -$0.319
FY27$739K$577K – $1.1M-$0.45-$0.51 – -$0.357
FY28$1.8M$1.4M – $2.6M-$0.45-$0.65 – -$0.1811
FY29$82.9M$64.7M – $119.0M-$0.34-$0.53 – -$0.245
FY30$299.9M$234.1M – $430.2M$0.02$0.01 – $0.035

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.18.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.98%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+58.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+65.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 200.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today82.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.575-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 168-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

AtaiBeckley Inc. (ATAI) signed a merger agreement on July 15, 2026 with Eli Lilly and Company, in which Lilly's subsidiary will acquire ATAI. Each share converts to $6.75 cash at closing plus one contingent value right (CVR) worth up to $2.50 per share upon specified clinical and regulatory milestones — for total consideration of up to $9.25 per share. The board unanimously approved the deal, which remains subject to customary closing conditions. This is a transformative acquisition by a top-five pharmaceutical company offering immediate cash liquidity plus milestone upside.

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

AtaiBeckley Inc. (ATAI) reported the results of its annual stockholder meeting held June 4, 2026, with 203,908,561 of approximately 366,916,896 eligible shares represented (a quorum). Three Class I directors — Sabrina Martucci Johnson, Amir Kalali M.D., and Andrea Heslin Smiley — were elected to serve through the 2029 annual meeting; Deloitte & Touche LLP was ratified as independent auditor for FY2026 with 201,864,060 votes in favor. All proposals passed. This is a routine annual meeting outcome with no surprises or contested votes.

8-KPress release / Reg FDJun 38-K — Item 7.01: Press release / Reg FD
AI summary

AtaiBeckley Inc. (ATAI) disclosed via Reg FD participation in four investor conferences in June 2026: Jefferies Global Healthcare (June 2-4, NYC), Oppenheimer CNS and Neuro-Muscular Summit (June 10, Miami), 7th Annual HCW Neuro Perspectives Hybrid Conference (June 15-16, virtual), and UBS Virtual CNS Day (June 15, virtual). Management planned to discuss program updates including initiation of the BPL-003 Phase 3 pivotal ReConnection program. The highlighted Phase 3 initiation is the most substantive signal for investors tracking the clinical pipeline.

3New insider — initial holdingsMar 133
8-KMaterial agreementMar 98-K — Item 1.01: Material agreement
S-3ASRAuto-shelf registrationMar 9S-3ASR
8-KPress release / Reg FDMar 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDFeb 268-K — Item 7.01: Press release / Reg FD
+ 19 other (12 proxys · 1 10-Q · 1 earnings 8-K · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders?prnewswire.com·17h agoWhy AtaiBeckley Stock Soared Todayfool.com·17h agoStock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billionfool.com·18h ago$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI)prnewswire.com·21h agoAtaiBeckley stock is soaring, and it has Eli Lilly to thankinvezz.com·21h ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ALLO
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport